Ruggaard & Associates’s Pfizer PFE Stock Holding History

Ruggaard & Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,667	Closed	-$213K	–	119
2024 Q1	$213K	Sell	7,667 -4,033	-34%	-$112K	0.1%	111
2023 Q4	$337K	Sell	11,700 -7,727	-40%	-$234K	0.18%	79
2023 Q3	$644K	Sell	19,427 -700	-3%	-$24.8K	0.38%	36
2023 Q2	$738K	Sell	20,127 -1,300	-6%	-$50.6K	0.43%	27
2023 Q1	$874K	Buy	+21,427	New	+$925K	0.54%	23

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Ruggaard & Associates's PFE Position: Q2 2024 in Review

Ruggaard & Associates sold out of Pfizer (PFE) in Q2 2024, closing a stake of 7,667 shares — an estimated $213K sold.

Ruggaard & Associates first reported a position in PFE in Q1 2023 and held it in 5 quarters. The position peaked at $874K in Q1 2023. 2,874 funds tracked by Wall St. Rank hold PFE as of Q2 2024.

Ruggaard & Associates reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
Ruggaard & Associates sold 7,667 Pfizer shares in Q2 2024, an estimated $213K.
Ruggaard & Associates first reported a position in Pfizer in Q1 2023 and held it in 5 quarters.
Ruggaard & Associates's Pfizer position peaked at $874K in Q1 2023.
2,874 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.

Based on Ruggaard & Associates's 13F filing for Q2 2024, filed 13 Aug 2024.